World High Life Investment Strategy Update
World High Life Plc (OTCQB:WRHLF) announced a strategic focus on expanding investments in the medicinal cannabis sector, driven by the success of its subsidiary, Love Hemp. The company aims to explore new technologies and synthetic cannabinoids, which could enhance wellness through innovative pharmaceutical applications. CEO David Stadnyk emphasized the company's commitment to pursuing opportunities in cannabinoid pharmaceuticals, capitalizing on the growth momentum of Love Hemp, despite challenges posed by COVID-19.
- World High Life is actively expanding its investment strategy in the medicinal cannabis sector.
- The company is focusing on innovative applications, including synthetic cannabinoids and CBD.
- Love Hemp's growth is providing a foundation for new strategic investments.
- The ongoing challenges from COVID-19 could impact overall business development.
Love Hemp momentum provides World High Life team with the opportunity to focus investment attention on innovative applications for medicinal cannabis, including synthetics, CBD, and Hemp
LONDON, UK / ACCESSWIRE / September 4, 2020 / World High Life Plc (AQSE:LIFE)(OTCQB:WRHLF) ("World High Life" or the "Company") is pleased to announce that, in accordance with the Company's investment strategy, and building upon momentum from its wholly owned subsidiary, London based Love Hemp Limited ("Love Hemp"), the Company is now actively considering investment targets in the medicinal cannabis space, including new technologies and synthetic cannabinoids with potential for wide applications in multiple jurisdictions.
"There are compelling opportunities to achieve our mandate, improving quality of life and wellness through innovations in medicinal cannabis, synthetic pharmaceutical derivatives, CBD and Hemp, with a number of investment opportunities that our team is actively pursuing," noted Mr. David Stadnyk, World High Life CEO.
World High Life Investment Strategy Highlights
Building on Love Hemp's continued growth, World High Life leadership is seeking new strategic investments in the medicinal cannabis sector, including pharmaceutical applications
Potential areas of interest include new technologies, synthetic cannabinoids, CBD, and Hemp, where they can be applied to scale globally
Within this scope, the Company intends to invest in and scale innovative, early stage, uses of cannabinoids, which have existing approvals in place to benefit patients/users
"The Love Hemp team is doing terrific work, advancing its business model under difficult circumstances, due to COVID-19, and growing on many fronts. That momentum has allowed our World High Life team to become more active on the investment side of our business as we see tremendous opportunities, especially in the cannabinoid pharmaceutical space," added Mr. Stadnyk.
For further information please contact:
David Stadnyk
Founder & CEO
North America: 1 (236) 521-7211
North America toll-free: 1 (888) 616-WRHLF (9745)
+44 (0) 7926 397 675
info@worldhighlife.uk
AQSE Corporate Adviser
Mark Anwyl/Allie Feuerlein
Peterhouse Capital Limited
+44 (0) 20 7469 0930
ma@peterhousecap.com
af@peterhousecap.com
Financial PR
Camilla Horsfall/Megan Ray
Blytheweigh
+44 (0) 20 7138 3224
Camilla.horsfall@blytheweigh.com
Megan.Ray@blytheweigh.com
For more information on World High Life please visit: www.worldhighlife.uk
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Cautionary Note Regarding Forward Looking Information
We seek safe harbour. Some statements contained in this news release are "forward looking information" within the meaning of securities laws. Forward looking information include, but are not limited to, statements regarding the use of proceeds of the non-brokered private placement and payment of the debt settlements. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual results to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. We do not undertake to update any estimate at any particular time or in response to any particular event, except as required by law.
SOURCE: World High Life Plc
View source version on accesswire.com:
https://www.accesswire.com/604745/World-High-Life-Investment-Strategy-Update
FAQ
What investment strategy is World High Life pursuing as of September 2020?
How is Love Hemp contributing to World High Life's growth?
What are the main areas of investment interest for World High Life?
What challenges is World High Life facing in the current market environment?
